Communiqués de presse

May 11, 2021
Miravo Healthcare^TM to Present at Q2 Virtual Investor Summit

May 3, 2021
Miravo Healthcare^TM Announces First Quarter 2021 Results Release Date and Virtual Annual Meeting of Shareholders

April 21, 2021
Miravo Healthcare^TM Files Final Base Shelf Prospectus

April 9, 2021
Miravo Healthcare^TM to Present at Upcoming Investor Conferences

March 26, 2021
Miravo Healthcare^TM Acknowledged in the Globe and Mail's Second Annual Women Lead Here Benchmark of Executive Gender Diversity

March 11, 2021
Miravo Healthcare^TM to Present at Q1 Virtual Investor Summit

March 8, 2021
Miravo Healthcare^TM Announces Fourth Quarter 2020 Results

March 8, 2021
Miravo Healthcare^TM Files Preliminary Base Shelf Prospectus

March 1, 2021
Miravo Healthcare^TM Ireland Enters into Resultz License and Supply Agreement with The Mentholatum Company for the United States

February 22, 2021
Miravo Healthcare^TM Announces Fourth Quarter 2020 Results Release Date and Conference Call Details

January 14, 2021
Miravo Healthcare^TM to Host Investor Webcast on January 28, 2021 at 2:00 pm EST

January 13, 2021
Miravo Healthcare^TM Announces the Canadian Commercial Launch of NeoVisc+ and NeoVisc ONE for the Treatment of Pain and Improvement of Joint Functionality of the Knee

December 18, 2020
Nuvo Pharmaceuticals® Announces Corporate Rebranding as Miravo Healthcare

November 16, 2020
Nuvo Pharmaceuticals® Announces Third Quarter 2020 Results

November 2, 2020
Nuvo Pharmaceuticals® Announces Third Quarter 2020 Results Release Date and Conference Call

October 5, 2020
Nuvo Pharmaceuticals® to Webcast Live at VirtualInvestorConferences.com October 8th

September 14, 2020
Nuvo Pharmaceuticals® to Webcast Live at Life Sciences Investor Forum September 17th

September 9, 2020
Nuvo Pharmaceuticals® Announces The Canadian Commercial Launch of Suvexx™ - For The Acute Treatment of Migraine

August 10, 2020
Nuvo Pharmaceuticals® Announces Second Quarter 2020 Results

July 27, 2020
Nuvo Pharmaceuticals™ Announces Second Quarter 2020 Results Release Date and Conference Call Details

May 12, 2020
Nuvo Pharmaceuticals® Announces Director Election Results of its Annual & Special Meeting of Shareholders

May 11, 2020
Nuvo Pharmaceuticals® Announces First Quarter 2020 Results

April 27, 2020
Nuvo Pharmaceuticals® Announces First Quarter 2020 Results Release Date and Virtual Annual & Special Meeting of Shareholders

March 31, 2020
Nuvo Pharmaceuticals® Announces Approval of Takeda's Cabpirin Tablets in Japan, Triggering a US$2.0 Million Milestone Payment due in Q2 2020

March 23, 2020
Nuvo Pharmaceuticals® to Webcast Live at Life Sciences Investor Forum March 26th

March 4, 2020
Nuvo Pharmaceuticals® Announces "at risk" Launch of Generic Version of Vimovo in the United States

February 27, 2020
Nuvo Pharmaceuticals® Announces Health Canada Approves Suvexx™ For The Acute Treatment of Migraine

February 25, 2020
Nuvo Pharmaceuticals® Announces 2019 and Fourth Quarter Results

February 11, 2020
Nuvo Pharmaceuticals™ Responds to Market Activity

February 11, 2020
Nuvo Pharmaceuticals™ Announces Fourth Quarter 2019 Results Release Date and Conference Call Details

January 7, 2020
Nuvo Pharmaceuticals™ Announces Repayment of Bridge Loan and Entitlement to Receive 2019 Vimovo U.S. Annual Minimum Royalty

November 11, 2019
Nuvo Pharmaceuticals™ Announces United States District Court Denies Dr. Reddy's Laboratories Motion for Summary Judgment of Nuvo's '996 and '920 VIMOVO Patents

October 31, 2019
Nuvo Pharmaceuticals™ Announces 2019 Third Quarter Results

October 17, 2019
Nuvo Pharmaceuticals™ Announces Third Quarter 2019 Results Release Date and Conference Call Details

September 9, 2019
Nuvo Pharmaceuticals™ Update to Nuvo's Presentation Time at H.C. Wainwright Global Investment Conference

September 4, 2019
Nuvo Pharmaceuticals™ to Present at H.C. Wainwright Global Investment Conference

August 14, 2019
Nuvo Pharmaceuticals™ Announces 2019 Second Quarter Results

August 7, 2019
Aralez Pharmaceuticals Canada Inc. and the Canadian Asthma, Allergy and Immunology Foundation (CAAIF) Announce Research Grant Award Winner

July 31, 2019
Nuvo Pharmaceuticals™ Announces Second Quarter 2019 Results Release Date and Conference Call Details

July 30, 2019
Nuvo Pharmaceuticals™ Provides VIMOVO Patent Update

June 26, 2019
Nuvo Pharmaceuticals™ Announces Director Election Results of its Annual General Meeting and Updates to the Facility Agreement with Deerfield

June 17, 2019
Nuvo Pharmaceuticals™ Provides Corporate Update

May 15, 2019
Nuvo Pharmaceuticals™ Announces that U.S. Court of Appeals for the Federal Circuit Reverses District Court's Decision Related to Certain Vimovo Patents

May 14, 2019
Nuvo Pharmaceuticals™ Announces 2019 First Quarter Results

April 23, 2019
Nuvo Pharmaceuticals™ to Present at the Bloom Burton & Co. Healthcare Investor Conference

April 2, 2019
Nuvo Pharmaceuticals™ Announces Pennsaid 2% Marketing Authorization Application Accepted for Review by AGES, the Austrian Agency for Health and Food Safety

March 29, 2019
Nuvo Pharmaceuticals™ Announces 2018 Fourth Quarter and Year-End Results

March 15, 2019
Nuvo Pharmaceuticals™ Announces the Filing of the Business Acquisition Report Related to the Acquisition of Aralez Pharmaceuticals Canada, U.S. and International Rights to Vimovo® and other Related Assets

March 11, 2019
Nuvo Pharmaceuticals™ Announces Receipt of Shareholder Approval By Way of Written Consent For the Issuance of Common Shares Pursuant to Convertible Notes and Warrants

January 3, 2019
Nuvo Pharmaceuticals™ Announces Appointment of Rob Harris as Executive Chairman

January 2, 2019

Nuvo Pharmaceuticals™ to Host Conference Call/Audio Webcast to Discuss the Acquisition of Aralez Pharmaceuticals Canada, U.S. and International Rights to Vimovo® and other Related Assets

December 31, 2018
Nuvo Pharmaceuticals™ Announces Completion of the Acquisition of Aralez Pharmaceuticals Canada, U.S. and International Rights to Vimovo® and other Related Assets

December 21, 2018
Nuvo Pharmaceuticals™ (Ireland) DAC Enters into Resultz® License and Supply Agreement with Heumann Pharma GmbH & Co. Generica KG for Germany

November 29, 2018
Nuvo Pharmaceuticals™ Pharmaceuticals™ Declared Winning Bidder to Acquire Commercial Products from Aralez Pharmaceuticals

November 8, 2018
Nuvo Pharmaceuticals™ Announces 2018 Third Quarter Results

September 19, 2018
Nuvo Pharmaceuticals™ Announces Signing of Definitive Agreements to Acquire Commercial Products and Infrastructure from Aralez Pharmaceuticals

August 20, 2018
Nuvo Pharmaceuticals™ Announces Extension of Exclusivity Period with Aralez and Deerfield

August 10, 2018
Nuvo Pharmaceuticals™ Announces Letter of Intent to Acquire Commercial Products and Infrastructure from Aralez Pharmaceuticals

August 2, 2018
Nuvo Pharmaceuticals™ Announces 2018 Second Quarter Results

July 23, 2018
Nuvo Pharmaceuticals™(Ireland) Limited Enters into Resultz® License and Supply Agreement with Fagron Belgium NV for Belgium, the Netherlands and Luxembourg

May 10, 2018
Nuvo Pharmaceuticals™ Announces Director Election Results of its Annual General Meeting

May 10, 2018
Nuvo Pharmaceuticals™ Announces 2018 First Quarter Results

March 23, 2018
Nuvo Pharmaceuticals™ Announces 2017 Fourth Quarter

January 15, 2018
Nuvo Pharmaceuticals (Ireland) Limited Acquires U.S. Product Rights to Resultz® from Piedmont Pharmaceuticals LLC

January 2, 2018
Nuvo Pharmaceuticals Inc.™ Acquires Global ex-U.S. Product Rights and existing Royalty Streams to Resultz® from Piedmont Pharmaceuticals LLC